+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunodeficient Mouse Models Market - Global Forecast 2026-2032- Product Image
Immunodeficient Mouse Models Market - Global Forecast 2026-2032- Product Image
Sale

Immunodeficient Mouse Models Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6278476
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Immunodeficient Mouse Models: Executive Overview

Immunodeficient mouse models are laboratory animals with reduced or absent immune functions, enabling research involving human cells, tissues, tumors, pathogens, and immune-system reconstruction. Their principal value lies in supporting controlled studies of disease biology, oncology, transplantation, infectious disease, gene and cell therapies, and pharmacology. Demand is shaped by the need for reproducible in vivo evidence, improved translational relevance, and more rigorous evaluation of therapies before clinical testing.

Translational Research Is Reshaping Model Selection

The field is moving from broadly immunosuppressed strains toward models selected for specific biological questions. Researchers increasingly distinguish between models that support human-cell engraftment, preserve particular innate immune functions, or permit reconstitution with human immune components. This shift places greater emphasis on genetic characterization, microbiological control, husbandry consistency, longitudinal monitoring, and transparent reporting of model limitations. Ethical review and the refinement, reduction, and replacement principles are also influencing study design and the choice of endpoints.

Artificial Intelligence Improves Design, Monitoring, and Interpretation

Artificial intelligence can strengthen immunodeficient mouse research by integrating phenotypic, genomic, imaging, and treatment-response data to identify informative model attributes. Computer vision may assist with standardized assessment of tumor burden, behavior, mobility, and welfare indicators, while machine-learning tools can support dose selection, cohort allocation, anomaly detection, and biomarker discovery. These applications do not remove the need for experimental validation: model bias, small datasets, inconsistent annotations, and limited cross-laboratory comparability can reduce reliability. Human oversight, auditable workflows, and independent replication remain essential.

Regional Research Priorities and Infrastructure Differ Across Markets

North America combines advanced biomedical research capacity with strong activity in oncology, immunology, transplantation, and therapeutic development. Europe emphasizes harmonized animal-welfare standards, reproducibility, and collaborative translational research. Asia-Pacific is supported by expanding biomedical infrastructure and substantial activity in oncology, regenerative medicine, and infectious disease research. Latin America is developing capabilities through academic and public research networks, with access to specialized colonies and advanced phenotyping remaining important considerations. The Middle East is strengthening biomedical and precision-medicine programs, while Africa is prioritizing infectious disease, immunology, and locally relevant health research; both regions benefit from partnerships that provide training, quality systems, and shared access to specialized facilities.

International Groups Shape Standards, Collaboration, and Access

ASEAN countries are building regional biomedical capacity and may benefit from shared repositories, harmonized protocols, and workforce development. BRICS members contribute substantial research diversity across infectious disease, oncology, and therapeutics, while collaboration must account for differing regulatory and infrastructure environments. The European Union supports cross-border research frameworks, animal-welfare governance, and data harmonization. G7 countries generally provide advanced scientific infrastructure and translational networks. GCC members are investing in biomedical and precision-health capabilities, creating opportunities for regional hubs. NATO members span mature and emerging research systems, making interoperability, biosafety, and coordinated preparedness relevant to collaborative model use.

Country-Level Capabilities Reflect Distinct Scientific and Regulatory Contexts

The United States and Canada have broad capabilities in preclinical research, advanced imaging, and therapeutic development. The United Kingdom, Germany, France, Italy, and Spain combine established biomedical institutions with detailed animal-research oversight and strong collaborative networks. Australia supports high-quality biomedical and infectious-disease research under structured regulatory controls. China, Japan, and South Korea maintain significant capabilities in oncology, immunology, biotechnology, and advanced laboratory methods. India is expanding translational and pharmaceutical research capacity. Brazil and Mexico are strengthening biomedical infrastructure and regional research networks. Russia retains capabilities across selected biomedical fields, although access to international collaboration, specialized resources, and harmonized standards can vary.

Leaders Should Prioritize Fit-for-Purpose Models and Evidence Quality

Industry leaders should define the biological question before selecting a strain, then document immune defects, engraftment performance, microbiological status, background genetics, sex, age, and husbandry conditions. Study plans should include predefined endpoints, appropriate controls, power calculations, welfare monitoring, and transparent reporting of exclusions. Partnerships with qualified facilities can improve colony quality, imaging, biosecurity, and reproducibility. Organizations should also invest in interoperable data systems, validated analytical tools, staff training, and independent replication. Where possible, combining immunodeficient models with organoids, ex vivo assays, and computational methods can reduce animal use while improving mechanistic interpretation.

Methodology: Evidence-Based Synthesis of Model Use and Research Drivers

This executive summary uses a structured qualitative synthesis of the supplied market scope, established scientific uses of immunodeficient mouse models, documented research practices, and recognized regulatory and translational considerations. Insights were organized across technology, application, geography, institutional groupings, and country context. The assessment emphasizes verifiable characteristics of model selection, infrastructure, oversight, and research application rather than financial estimates or forecasts. Because capabilities differ among institutions within each geography, regional and country observations are presented as broad, evidence-oriented patterns rather than uniform conditions.

Reliable Translation Depends on Integrated Model Governance

Immunodeficient mouse models remain important tools for studying human biology and evaluating therapeutic concepts, but their usefulness depends on biological fit, rigorous controls, and transparent interpretation. The strongest research programs combine well-characterized animals with human-relevant assays, advanced analytics, robust welfare practices, and reproducible data management. As artificial intelligence and precision biomedical methods mature, disciplined validation and cross-institutional standards will be central to converting model results into credible translational evidence.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunodeficient Mouse Models Market, by Model Type
7.1. Introduction
7.2. Chimeric And Reporter Models
7.3. Humanized Models
7.3.1. Hematopoietic Stem Cell Humanized
7.3.2. Patient Derived Xenograft Humanized
7.3.3. Peripheral Blood Lymphocyte Humanized
7.3.4. Tissue Humanized (BLT)
7.4. Standard Immunodeficient
7.4.1. Compound And Multi Mutant Models
7.4.2. NOD-SCID
7.4.3. NOG/NSG (NOD Scid Gamma)
7.4.4. Nude (Foxn1nu)
7.4.5. Rag1/Rag2 Knockout
7.4.6. SCID (Prkdc)
8. Immunodeficient Mouse Models Market, by Immunodeficiency Type
8.1. Introduction
8.2. B Cell Deficient
8.3. Combined Immunodeficiency
8.4. Cytokine Signaling Defects
8.5. Innate Immunity Defects
8.6. T Cell Deficient
9. Immunodeficient Mouse Models Market, by Genetic Alteration
9.1. Introduction
9.2. CRISPR Edited
9.3. Knockin
9.4. Knockout
9.4.1. Multi Gene Knockout
9.4.2. Single Gene Knockout
9.5. Spontaneous Mutant
9.6. Transgenic
10. Immunodeficient Mouse Models Market, by Strain Background
10.1. Introduction
10.2. BALB/c Background
10.3. C57BL/6 Background
10.4. Mixed Or Hybrid Background
10.5. NOD Background
11. Immunodeficient Mouse Models Market, by Product Format
11.1. Introduction
11.2. Cryopreserved Embryos
11.3. Cryopreserved Sperm
11.4. Live Animals
11.5. PDX Material And Tumor Banks
11.6. Service Deliverables (Breeding, Engraftment)
12. Immunodeficient Mouse Models Market, by Supply Type
12.1. Introduction
12.2. Breeding Colony Management
12.3. Cryorepository Access
12.4. Custom Generation
12.5. Off The Shelf
12.6. Short Term Loan Or Study Supply
13. Immunodeficient Mouse Models Market, by Application
13.1. Introduction
13.2. Autoimmunity
13.3. Immuno Oncology
13.4. Infectious Disease
13.5. Microbiome Studies
13.6. Oncology
13.6.1. Cell Line Xenograft
13.6.2. Patient Derived Xenograft
13.7. Pharmacology And Toxicology
13.8. Regenerative Medicine
13.9. Transplantation Research
13.10. Vaccine Research
14. Immunodeficient Mouse Models Market, by End User
14.1. Introduction
14.2. Academic And Research Institutes
14.3. Biotechnology Companies
14.4. Contract Research Organizations
14.5. Hospitals And Clinical Research Centers
14.6. Pharmaceutical Companies
15. Immunodeficient Mouse Models Market, by Region
15.1. Introduction
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Europe
15.6. Middle East
15.7. Africa
16. Immunodeficient Mouse Models Market, by Group
16.1. Introduction
16.2. ASEAN
16.3. GCC
16.4. European Union
16.5. BRICS
16.6. G7
16.7. NATO
17. Immunodeficient Mouse Models Market, by Country
17.1. Introduction
17.2. United States
17.3. Canada
17.4. Mexico
17.5. Brazil
17.6. United Kingdom
17.7. Germany
17.8. France
17.9. Russia
17.10. Italy
17.11. Spain
17.12. China
17.13. India
17.14. Japan
17.15. Australia
17.16. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. Market Concentration Analysis, 2025
18.2.1. Concentration Ratio (CR)
18.2.2. Herfindahl Hirschman Index (HHI)
18.3. Recent Developments & Impact Analysis, 2025
18.4. Product Portfolio Analysis, 2025
18.5. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Applied StemCell, Inc.
19.2. AXENIS SAS
19.3. Beijing Vitalstar Biotechnology Co., Ltd.
19.4. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
19.5. Champions Oncology, Inc.
19.6. Charles River Laboratories, Inc.
19.7. Crown Bioscience, Inc.
19.8. Envigo RMS, LLC
19.9. GemPharmatech Co., Ltd.
19.10. GenOway SA
19.11. Hera BioLabs, Inc.
19.12. Janvier Labs SAS
19.13. Shanghai Model Organisms Center, Inc.
19.14. Taconic Biosciences, Inc.
19.15. The Jackson Laboratory
19.16. Transgenic Inc.
19.17. Valbiotech Co., Ltd.
20. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immunodeficient Mouse Models Market, Years Considered for the Study
FIGURE 2. Global Immunodeficient Mouse Models Market, Research Design
FIGURE 3. Global Immunodeficient Mouse Models Market, Research Framework
FIGURE 4. Global Immunodeficient Mouse Models Market, Data Triangulation
FIGURE 5. Global Immunodeficient Mouse Models Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immunodeficient Mouse Models Market Size, by Model Type, 2025 vs 2032 (%)
FIGURE 7. Global Immunodeficient Mouse Models Market Size, by Model Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2025 vs 2032 (%)
FIGURE 9. Global Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2025 vs 2032 (%)
FIGURE 11. Global Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immunodeficient Mouse Models Market Size, by Strain Background, 2025 vs 2032 (%)
FIGURE 13. Global Immunodeficient Mouse Models Market Size, by Strain Background, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immunodeficient Mouse Models Market Size, by Product Format, 2025 vs 2032 (%)
FIGURE 15. Global Immunodeficient Mouse Models Market Size, by Product Format, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immunodeficient Mouse Models Market Size, by Supply Type, 2025 vs 2032 (%)
FIGURE 17. Global Immunodeficient Mouse Models Market Size, by Supply Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Immunodeficient Mouse Models Market Size, by Application, 2025 vs 2032 (%)
FIGURE 19. Global Immunodeficient Mouse Models Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Immunodeficient Mouse Models Market Size, by End User, 2025 vs 2032 (%)
FIGURE 21. Global Immunodeficient Mouse Models Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Immunodeficient Mouse Models Market Size, by Region, 2025 vs 2032 (%)
FIGURE 23. Global Immunodeficient Mouse Models Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Immunodeficient Mouse Models Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Immunodeficient Mouse Models Market Size, by Country, 2025 vs 2032 (%)
FIGURE 26. Global Immunodeficient Mouse Models Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Immunodeficient Mouse Models Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immunodeficient Mouse Models Market Segmentation & Coverage
TABLE 2. Global Immunodeficient Mouse Models Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 4. Global Chimeric And Reporter Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Chimeric And Reporter Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Chimeric And Reporter Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Humanized Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Humanized Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Humanized Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Hematopoietic Stem Cell Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Hematopoietic Stem Cell Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Hematopoietic Stem Cell Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Patient Derived Xenograft Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Patient Derived Xenograft Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Patient Derived Xenograft Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Peripheral Blood Lymphocyte Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Peripheral Blood Lymphocyte Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Peripheral Blood Lymphocyte Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Tissue Humanized (BLT) Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Tissue Humanized (BLT) Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Tissue Humanized (BLT) Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Standard Immunodeficient Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Standard Immunodeficient Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Standard Immunodeficient Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Compound And Multi Mutant Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Compound And Multi Mutant Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Compound And Multi Mutant Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global NOD-SCID Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global NOD-SCID Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global NOD-SCID Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global NOG/NSG (NOD Scid Gamma) Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global NOG/NSG (NOD Scid Gamma) Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global NOG/NSG (NOD Scid Gamma) Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Nude (Foxn1nu) Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Nude (Foxn1nu) Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Nude (Foxn1nu) Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Rag1/Rag2 Knockout Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Rag1/Rag2 Knockout Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Rag1/Rag2 Knockout Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global SCID (Prkdc) Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global SCID (Prkdc) Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global SCID (Prkdc) Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 44. Global B Cell Deficient Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global B Cell Deficient Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global B Cell Deficient Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Combined Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Combined Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Combined Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Cytokine Signaling Defects Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Cytokine Signaling Defects Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Cytokine Signaling Defects Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Innate Immunity Defects Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Innate Immunity Defects Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Innate Immunity Defects Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global T Cell Deficient Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global T Cell Deficient Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global T Cell Deficient Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 60. Global CRISPR Edited Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global CRISPR Edited Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global CRISPR Edited Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Knockin Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Knockin Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Knockin Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Knockout Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Knockout Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Knockout Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Multi Gene Knockout Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Multi Gene Knockout Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Multi Gene Knockout Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Single Gene Knockout Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Single Gene Knockout Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Single Gene Knockout Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Spontaneous Mutant Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Spontaneous Mutant Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Spontaneous Mutant Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Transgenic Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Transgenic Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Transgenic Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 82. Global BALB/c Background Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global BALB/c Background Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global BALB/c Background Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global C57BL/6 Background Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global C57BL/6 Background Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global C57BL/6 Background Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Mixed Or Hybrid Background Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Mixed Or Hybrid Background Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Mixed Or Hybrid Background Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global NOD Background Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global NOD Background Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global NOD Background Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 95. Global Cryopreserved Embryos Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Cryopreserved Embryos Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Cryopreserved Embryos Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Cryopreserved Sperm Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Cryopreserved Sperm Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Cryopreserved Sperm Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Live Animals Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Live Animals Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Live Animals Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global PDX Material And Tumor Banks Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global PDX Material And Tumor Banks Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global PDX Material And Tumor Banks Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Service Deliverables (Breeding, Engraftment) Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Service Deliverables (Breeding, Engraftment) Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Service Deliverables (Breeding, Engraftment) Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 111. Global Breeding Colony Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Breeding Colony Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Breeding Colony Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Cryorepository Access Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Cryorepository Access Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Cryorepository Access Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Custom Generation Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Custom Generation Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Custom Generation Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Off The Shelf Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Off The Shelf Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Off The Shelf Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Short Term Loan Or Study Supply Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Short Term Loan Or Study Supply Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Short Term Loan Or Study Supply Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. Global Autoimmunity Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Autoimmunity Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Autoimmunity Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Immuno Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Immuno Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Immuno Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Microbiome Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Microbiome Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Microbiome Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Cell Line Xenograft Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Cell Line Xenograft Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Cell Line Xenograft Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Patient Derived Xenograft Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global Patient Derived Xenograft Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global Patient Derived Xenograft Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global Pharmacology And Toxicology Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Pharmacology And Toxicology Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Pharmacology And Toxicology Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Regenerative Medicine Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Global Regenerative Medicine Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. Global Regenerative Medicine Market Size, by Country, 2017-2032 (USD Million)
TABLE 154. Global Transplantation Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Transplantation Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Transplantation Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Vaccine Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Vaccine Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Vaccine Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Hospitals And Clinical Research Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Hospitals And Clinical Research Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Hospitals And Clinical Research Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Asia-Pacific Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Asia-Pacific Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 179. Asia-Pacific Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 180. Asia-Pacific Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 181. Asia-Pacific Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 182. Asia-Pacific Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 183. Asia-Pacific Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 184. Asia-Pacific Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 185. Asia-Pacific Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 186. Asia-Pacific Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 187. Asia-Pacific Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 188. Asia-Pacific Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 189. Asia-Pacific Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. North America Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. North America Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 192. North America Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 193. North America Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 194. North America Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 195. North America Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 196. North America Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 197. North America Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 198. North America Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 199. North America Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 200. North America Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 201. North America Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 202. North America Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Latin America Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 204. Latin America Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 205. Latin America Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 206. Latin America Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 207. Latin America Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 208. Latin America Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 209. Latin America Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 210. Latin America Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 211. Latin America Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 212. Latin America Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 213. Latin America Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 214. Latin America Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 215. Latin America Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Europe Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 217. Europe Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 218. Europe Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 219. Europe Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 220. Europe Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 221. Europe Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 222. Europe Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 223. Europe Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 224. Europe Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 225. Europe Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 226. Europe Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 227. Europe Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 228. Europe Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Middle East Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 230. Middle East Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 231. Middle East Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 232. Middle East Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 233. Middle East Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 234. Middle East Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 235. Middle East Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 236. Middle East Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 237. Middle East Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 238. Middle East Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 239. Middle East Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 240. Middle East Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 241. Middle East Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. Africa Immunodeficient Mouse Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 243. Africa Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 244. Africa Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 245. Africa Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 246. Africa Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 247. Africa Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 248. Africa Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 249. Africa Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 250. Africa Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 251. Africa Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 252. Africa Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. Africa Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 254. Africa Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 255. Global Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 256. ASEAN Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 257. ASEAN Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 258. ASEAN Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 259. ASEAN Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 260. ASEAN Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 261. ASEAN Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 262. ASEAN Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 263. ASEAN Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 264. ASEAN Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 265. ASEAN Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 266. ASEAN Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 267. ASEAN Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 268. ASEAN Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. GCC Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 270. GCC Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 271. GCC Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 272. GCC Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 273. GCC Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 274. GCC Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 275. GCC Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 276. GCC Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 277. GCC Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 278. GCC Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 279. GCC Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 280. GCC Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 281. GCC Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. European Union Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. European Union Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 284. European Union Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 285. European Union Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 286. European Union Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 287. European Union Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 288. European Union Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 289. European Union Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 290. European Union Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 291. European Union Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 292. European Union Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 293. European Union Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 294. European Union Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 295. BRICS Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. BRICS Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 297. BRICS Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 298. BRICS Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 299. BRICS Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 300. BRICS Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 301. BRICS Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 302. BRICS Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 303. BRICS Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 304. BRICS Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 305. BRICS Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 306. BRICS Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 307. BRICS Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. G7 Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 309. G7 Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 310. G7 Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 311. G7 Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 312. G7 Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 313. G7 Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 314. G7 Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 315. G7 Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 316. G7 Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 317. G7 Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 318. G7 Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 319. G7 Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 320. G7 Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 321. NATO Immunodeficient Mouse Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 322. NATO Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 323. NATO Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 324. NATO Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 325. NATO Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 326. NATO Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 327. NATO Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 328. NATO Immunodeficient Mouse Models Market Size, by Strain Background, 2017-2032 (USD Million)
TABLE 329. NATO Immunodeficient Mouse Models Market Size, by Product Format, 2017-2032 (USD Million)
TABLE 330. NATO Immunodeficient Mouse Models Market Size, by Supply Type, 2017-2032 (USD Million)
TABLE 331. NATO Immunodeficient Mouse Models Market Size, by Application, 2017-2032 (USD Million)
TABLE 332. NATO Immunodeficient Mouse Models Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 333. NATO Immunodeficient Mouse Models Market Size, by End User, 2017-2032 (USD Million)
TABLE 334. Global Immunodeficient Mouse Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 335. United States Immunodeficient Mouse Models Market Size, 2017-2032 (USD Million)
TABLE 336. United States Immunodeficient Mouse Models Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 337. United States Immunodeficient Mouse Models Market Size, by Humanized Models, 2017-2032 (USD Million)
TABLE 338. United States Immunodeficient Mouse Models Market Size, by Standard Immunodeficient, 2017-2032 (USD Million)
TABLE 339. United States Immunodeficient Mouse Models Market Size, by Immunodeficiency Type, 2017-2032 (USD Million)
TABLE 340. United States Immunodeficient Mouse Models Market Size, by Genetic Alteration, 2017-2032 (USD Million)
TABLE 341. United States Immunodeficient Mouse Models Market Size, by Knockout, 2017-2032 (USD Million)
TABLE 342. United States Immunodeficient Mouse Models Market Size, b

Companies Mentioned

  • Applied StemCell, Inc.
  • AXENIS SAS
  • Beijing Vitalstar Biotechnology Co., Ltd.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  • Champions Oncology, Inc.
  • Charles River Laboratories, Inc.
  • Crown Bioscience, Inc.
  • Envigo RMS, LLC
  • GemPharmatech Co., Ltd.
  • GenOway SA
  • Hera BioLabs, Inc.
  • Janvier Labs SAS
  • Shanghai Model Organisms Center, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Transgenic Inc.
  • Valbiotech Co., Ltd.

Related Topics

Related Reports

Animal Model: Market Share, and Growth Analysis by Product Type (Transgenic Models, Knockout Models, Hybrid Models, Immunodeficient Models), Application, End User, Technology - Product Image

Animal Model: Market Share, and Growth Analysis by Product Type (Transgenic Models, Knockout Models, Hybrid Models, Immunodeficient Models), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030 - Product Image

Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030

  • Report
  • 380 Pages
  • Global
From
Immuno-oncology and Immunotherapy Part E. Methods in Cell Biology Volume 199 - Product Image

Immuno-oncology and Immunotherapy Part E. Methods in Cell Biology Volume 199

  • Book
Immuno-oncology and Immunotherapy Part F. Methods in Cell Biology Volume 201 - Product Image

Immuno-oncology and Immunotherapy Part F. Methods in Cell Biology Volume 201

  • Book
Immuno-oncology and Immunotherapy Part D. Methods in Cell Biology Volume 196 - Product Image

Immuno-oncology and Immunotherapy Part D. Methods in Cell Biology Volume 196

  • Book
Copyright © 2002-2026 Research and Markets. All Rights Reserved.